Original vs generic drugs in treatment of chronic myeloid leukaemia
Journal Title: OncoReview - Year 2014, Vol 4, Issue 3
Abstract
The beginning of the twenty-first century saw a breakthrough in haematology, oncology and general medicine driven by the introduction of imatinib (Glivec) to the treatment of chronic myeloid leukaemia. For the first time, a neoplastic disease was successfully treated by a therapy targeting the genetic cause of the disease. At present, targeted therapy based on imatinib is the first one to enter a new stage which is the launch of generic drugs. Poland is the first country in the European Union which, from the beginning of July 2014, introduced generic imatinib. Hence, there is no reliable data on its use except for results from bioequivalence tests. The only data available comes from developing countries where other preparations are used, without reliable bioequivalence studies. However, all generic drugs of imatinib registered in Poland have successfully passed such tests. Undoubtedly, it is necessary to appropriately monitor patients with chronic myeloid leukaemia receiving generic drugs in order to ensure their safety and provide information to other countries where therapy based on generic drugs will be introduced in the following years.
Authors and Affiliations
Patrycja Rusicka
Keywords
Related Articles
- EP ID EP67764
- DOI -
- Views 205
- Downloads 0
Knowledge about prevention, risk factors and treatment in women with diagnosed breast cancer. Whether the disease affects their healthy behaviour?
Objective. The assessment of knowledge about prevention and risk factors of women with diagnosed breast cancer.Material and methods. The study involved 100 women aged from 28 to 82 years (median 56.2 years) who were trea...
Leczenie nadpłytkowości samoistnej w ciąży - doświadczenia własne ośrodka
Nadpłytkowość samoistna (ET) jest przewlekłym nowotworem mieloproliferacyjnym dotyczącym głównie linii megakariocytów, przebiegającym ze zwiększoną ponad 450 000/ul liczbą płytek krwi. Nadpłytkowość występuje przede wszy...
Off-label drug use in breast cancer therapy
Breast cancer is one of the most common malignancies across the world, including Poland. Chemotherapy plays an important part in the treatment of the disease. Most of the available chemotherapy drugs and regimens have un...
IgM multiple myeloma: diagnostic difficulties and results of bortezomib treatment – case report
The IgM paraprotein secretion is most frequently associated with Waldenström’s macroglobulinemia. In very rare cases it may also occur in multiple myeloma. The diagnostic and therapeutic process of a 84 year old male suf...
The evaluation of the efficacy and toxicity of targeted treatment in non-small cell lung cancer patients – single centre experience
Introduction: Tyrosine kinase inhibitors (TKI) are the standard of treatment in patients with advanced non-small cell lung cancer (NSCLC) with EGFR (endothelial growth factor receptor) gene activating mutation. Objecti...